Oncology
3 drugs are in development for Epithelial Ovarian Cancer.
- Companies
- 3
- Clinical trials
- 23
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Epithelial Ovarian Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Lorigerlimab | MACROGENICS INC (MGNX) |
Phase 1(2)
| Drug | Company |
|---|---|
| CT-95 | Context Therapeutics Inc. (CNTX) |
| itil-306 | Instil Bio, Inc. (TIL) |
About this indication
Epithelial Ovarian Cancer context
Oncology·MeSH: Carcinoma, Ovarian Epithelial (D000077216)
Also known as: Cancer, Ovarian Epithelial, Carcinoma, Epithelial Ovarian, Epithelial Ovarian Cancers, Epithelial Ovarian Carcinomas, Ovarian Epithelial Cancers, Ovarian Epithelial Carcinoma, Ovarian Epithelial Carcinomas
Prevalence
24.0 / 100K
Incidence
10.6 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Epithelial Ovarian Cancer?
BioSniper tracks 3 drugs in development for Epithelial Ovarian Cancer across 3 companies.
How many clinical trials target Epithelial Ovarian Cancer?
There are 23 clinical trials targeting Epithelial Ovarian Cancer tracked by BioSniper.
What is the prevalence of Epithelial Ovarian Cancer?
The estimated prevalence of Epithelial Ovarian Cancer is approximately 24.0 per 100,000 population.